Treatment patterns and best response in a contemporary cohort of patients with relapsed/refractory chronic lymphocytic leukemia with 17p deletion

被引：0
|
作者：
Lamanna, Nicole
Hurst, Deborah
Latremouille-Viau, Dominick
Ionescu-Ittu, Raluca
Guerin, Annie
Yim, Yeun Mi
Reyes, Carolina
机构：
[1] Herbert Irving Comprehens Canc Ctr, Hematol Malignancies Sect, New York, NY USA
[2] Genentech Inc, San Francisco, CA 94080 USA
[3] Anal Grp Inc, Montreal, PQ, Canada
来源：
LEUKEMIA & LYMPHOMA | 2015年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
175
引用
收藏
页码：147 / 148
页数：2
相关论文
共 50 条
  • [21] Economic Evaluation for the US of Venetoclax Versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion
    Alsaid, Nimer
    McBride, Ali
    Oh, Mok
    Persky, Daniel
    Anwer, Faiz
    Andritsos, Leslie
    Kumar, Abhijeet
    Yun, Seongseok
    Abraham, Ivo
    BLOOD, 2017, 130
  • [22] What Do We Do with Chronic Lymphocytic Leukemia with 17p Deletion?
    Sellner, L.
    Denzinger, S.
    Dietrich, S.
    Glimm, H.
    Merkel, O.
    Dreger, P.
    Zenz, T.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2013, 8 (01) : 81 - 90
  • [23] 17p Deletion in Chronic Lymphocytic Leukemia Risk Stratification and Therapeutic Approach
    Schnaiter, Andrea
    Stilgenbauer, Stephan
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2013, 27 (02) : 289 - +
  • [24] What Do We Do with Chronic Lymphocytic Leukemia with 17p Deletion?
    L. Sellner
    S. Denzinger
    S. Dietrich
    H. Glimm
    O. Merkel
    P. Dreger
    T. Zenz
    Current Hematologic Malignancy Reports, 2013, 8 : 81 - 90
  • [25] 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia
    Bagacean, Cristina
    Tempescul, Adrian
    Ternant, David
    Banet, Anne
    Douet-Guilbert, Nathalie
    Bordron, Anne
    Bendaoud, Boutahar
    Saad, Hussam
    Zdrenghea, Mihnea
    Berthou, Christian
    Paintaud, Gilles
    Renaudineau, Yves
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [26] Overall survival among patients diagnosed with B-chronic lymphocytic leukemia with 17p deletion status (del(17p))
    Katalinic, D.
    Toetome, L.
    Bildat, S.
    Kattner, E.
    Aleric, I.
    Vcev, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 223 - 223
  • [27] Chronic Lymphocytic Leukemia With Deletion 17p: Emerging Treatment Options THE STEPHENS/BYRD ARTICLE REVIEWED
    Jain, Nitin
    O'Brien, Susan
    ONCOLOGY-NEW YORK, 2012, 26 (11): : 1067 - +
  • [28] Outcomes of first-line treatment for chronic lymphocytic leukemia (CLL) with 17p deletion (del17p)
    Strati, Paolo
    Keating, Michael J.
    O'Brien, Susan Mary
    Ferrajoli, Alessandra
    Burger, Jan Andreas
    Faderl, Stefan
    Jain, Nitin
    Wierda, William G.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] Results from the phase 2 RESONATE™-17 Trial: Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic leukaemia with 17p deletion
    Munir, T.
    O'Brien, S.
    Jones, J. A.
    Coutre, S. E.
    Mato, A. R.
    Hillmen, P.
    Tam, C.
    Osterborg, A.
    Siddiqi, T.
    Thirman, M. J.
    Furman, R. R.
    Ilhan, O.
    Keating, M.
    Call, T. G.
    Brown, J. R.
    Stevens-Brogan, M.
    Li, Y.
    Clow, F.
    James, D.
    Chu, A.
    Hallek, M.
    Stilgenbauer, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 : 71 - 71
  • [30] A case of chronic lymphocytic leukemia with deletion 17p and bilateral retinal leukemic infiltrates
    Treppendahl, Marianne Bach
    Andersen, Nis
    Jurlander, Jesper
    Geisler, Christian
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2009, 82 (01) : 79 - 80
12345